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Abbreviations
and Acronyms
AF = atrial ﬁbrillation
ASA = aspirin
bid = twice daily
CAD = coronary artery
disease
CI = conﬁdence interval
CrCl = creatinine clearance
DE = dabigatran etexilate
DE 110 = dabigatran
etexilate 110 mg twice daily
DE 150 = dabigatran
etexilate 150 mg twice daily
PK = pharmacokinetic(s)
SEE = systemic embolic
event(s)
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322Dabigatran etexilate (DE), a new,
oral, direct thrombin inhibitor
was shown in the RE-LY (Ran-
domized Evaluation of Long-
Term Anticoagulation Therapy)
trial to be as effective (110 mg
twice daily [bid], DE 110) or
more effective (150 mg bid, DE
150) than warfarin, when given
as a ﬁxed dose without laboratory
monitoring for prevention of st-
roke and systemic embolism in
atrial ﬁbrillation (AF) patients
(1–3). The low dose of DE was
associated with signiﬁcantly less
bleeding than both warfarin and
the high dose of DE. Compared
with DE 110, exposure to dabi-
gatran was increased by 36%with DE 150 (4), resulting in a 39% reduction in strokes/
systemic emboli but at the cost of a 16% increase in major
bleeding (1,2). Thus, the RE-LY trial established dose–
response relationships for stroke prevention and bleeding
with DE. However, there is large variability in the plasma
concentrations achieved with any given dose, depending on
absorption, renal function, and other patient factors (4–6).
DE is a prodrug metabolized in the plasma and liver to
the active moiety dabigatran (6). How much the risk of
stroke or bleeding also varies across the concentration range
has important implications for the beneﬁt–risk ratio and
the possibility to tailor the dose in individual patients.
Currently, it is unknown whether there is a single concen-
tration range where the balance between thromboembolic
events and bleeding events is optimal for all AF patients.
The rates of stroke and major bleeding in DE-treated
patients have been investigated across a variety of patient
subgroups (1,7), but correlations of stroke and bleeding risk
with individual plasma concentrations have not been pre-
sented. The aims of this pharmacokinetic (PK) analysis of
the RE-LY trial were to explore the association between
plasma concentrations and efﬁcacy and safety outcomes,
and to identify factors affecting the variability of plasma
concentrations of dabigatran and their impact on outcome
events in AF patients with an indication for oral
anticoagulation.
Methods
The design and results of the RE-LY study have been
previously published (1–3). Brieﬂy, the primary objective of
RE-LY was to establish the noninferiority of 2 doses of DE
compared with warfarin for stroke prevention in patients
with AF and 1 additional risk factor for stroke. This trial
randomized 18,113 AF patients to 1 of 2 blinded doses of
DE, DE 110 or DE 150, or to dose-adjusted warfarin
titrated to an international normalized ratio of 2 to 3.Median follow-up was 2.0 years. The study, including the
PK sampling, was approved by all appropriate national
regulatory authorities and ethics committees. All patients
provided written informed consent before study entry.
All patients with a valid blood sample and all ischemic
stroke/systemic embolic events (SEE) or bleeding events
that occurred on-treatment in these patients were included
in the analysis, regardless of when the event occurred in
relation to the sampling. Patients who were off-treatment at
the time of sampling or the time of event were not included
in the analysis. All primary and secondary outcome events
were blindly and doubly adjudicated. The primary RE-LY
study outcome was stroke or systemic embolism. Stroke
type was subdivided into ischemic, hemorrhagic, and
unknown. Deﬁnitions of RE-LY endpoints are described
elsewhere (1,3). CHADS2 score is a simple validated risk
score that assigns 1 point for a history of congestive heart
failure, hypertension, age 75 years or older, and diabetes
mellitus and 2 points for a history of stroke or transient
ischemic attack. CHA2DS2-VASc (8) and HAS-BLED (9)
are other methods to assess risk for stroke or bleeding in AF
patients.
PK and statistical methods. Peak and trough samples at
steady state were collected for determination of drug
concentration, activated partial thromboplastin time, and
ecarin clotting time at 1-month post-randomization in all
DE subjects who gave consent to participate, regardless of
the time of any ischemic or bleeding event that occurred.
Samples were collected from patients in all geographic
regions. The frequencies generally approximated the number
of recruited subjects. For trough concentrations, only
samples collected within 10 to 16 h after the previous DE
dose were considered. Similarly, for post-dose samples, only
samples collected within 1 to 3 h after dosing were
considered. Approximately 12% of samples were excluded
from evaluation because of questionable records in blood
sampling date/time or in administration date/time. Addi-
tional samples were taken at 3, 6, and 12 months from 2,143
subjects who participated in a PK substudy. For analyses
reported here, the data were merged with the data from the
substudy and analyzed together. The ﬁrst trough and post-
dose samples fulﬁlling the time-window rule were used
from these subjects with multiple blood samples. The pop-
ulation PK (4) and pharmacodynamic data (activated partial
thromboplastin time and ecarin clotting time) will be re-
ported elsewhere.
Plasma concentrations of nonconjugated (free) dabigatran
and of total dabigatran after alkaline cleavage of conjugates
were determined by a validated high-performance liquid
chromatography tandem mass spectrometry method at
AAIPharma Deutschland GmbH & Co. KG, Neu-Ulm,
Germany (10). Total dabigatran concentration was deter-
mined in all PK plasma samples, whereas nonconjugated
dabigatran was determined in a subset (n ¼ 1,085) of
samples in order to assess the prevalence of dabigatran
acylglucuronides in this population.
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323Logistic regression of events (ischemic stroke/SEE and
major and minor bleeds) and associated log-transformed
trough plasma concentrations was performed with and
without covariates. If patients had more than 1 observation,
the sample closest to the planned time after dose (2 h and
12 h) was used, regardless of the occurrence of an event.
The best-ﬁt model was deﬁned based on the Akaike
Information Criterion. The c-statistic for predictive value
based on the receiver-operating characteristic curve was also
calculated. The impact of the covariates age, sex, body mass
index, creatinine clearance (CrCl), coronary artery disease
(CAD), diabetes mellitus, prior stroke or transient ischemic
attack, hypertension, heart failure, CHADS2 score,
concomitant aspirin (ASA) use, and concomitant clopi-
dogrel use were investigated. Only covariates with p < 0.2
were retained in the model if the Akaike Information
Criterion was improved. CrCl at baseline was calculated
using the Cockroft-Gault equation.
The performance of the ﬁnal logistic regression models
for major bleeding and ischemic stroke/SEE was tested by
predicting the event rates in the DE patients without plasma
concentration measurements (n ¼ 3,584). For these patients,
the validation dataset, the trough plasma concentrations, was
predicted using the population PK model from RE-LY (4),
and the individual stroke and bleed rates were calculated
based on the ﬁnal logistic regression models. Patients were
sorted according to their calculated risk and divided into
ascending deciles. For each decile, the mean predicted risks
for an event and for no event were calculated and compared
with observed rates. The predictive performance was evalu-
ated by the Hosmer-Lemeshow test (Online Table 1, Online
Fig. 1). Values of p > 0.05 indicate no signiﬁcant difference
between the predicted and observed event rates.
Post-dose concentrations provided no advantages
compared with trough concentrations, so only the latter are
reported in the logistic regression analyses. Cox regression
spline analyses were performed to explore the covariate–
concentration–response relationship without the restrictions
of a covariate linear effect. Event rates for bleeding and
thromboembolic events are for the entire duration of theTable 1
Plasma Concentrations of Total Dabigatran After Oral Admin
Dose-Normalized Concentrations
DE 110
(ng/ml)
Cpre,ss
(n ¼ 4,227)
C2,ss
(n ¼ 4,583)
Cpre,ss
(n ¼ 4,222
gMean 64.7 126 91
gCV, % 79.9 75.3 81.9
Median 65.9 133 93
P10 28.2 52 39.8
P90 155 275 215
Min 1.15 1.07 1.04
Max 608 745 809
bid ¼ twice daily; C2,ss ¼ 2-h post-dose plasma concentration at steady state; Cpre,ss ¼ pre-dose plasma co
daily; DE 150 ¼ dabigatran etexilate 150 mg twice daily; gCV ¼ geometric coefﬁcient of variation; gMetrial (median duration 2.0 years). All statistical analyses
were performed with SAS version 9.1 and higher (SAS
Institute, Cary, North Carolina).
Results
Plasma concentrations of dabigatran were available from
9,183 and 8,449 patients for peak and trough measurements,
respectively (76% and 70% of randomized patients). The
geometric mean trough concentrations were 64.7 and 91.0
ng/ml for the DE 110 and DE 150 doses, respectively, with
10th to 90th percentiles of 28.2 to 155 ng/ml for DE 110
and 39.8 to 215 ng/ml for DE 150, a 5.2- to 5.5-fold range
of variation (Table 1). Geometric mean trough concentra-
tions were 41% higher for the DE 150 dose compared with
the DE 110 dose, and peak concentrations were 38% higher,
demonstrating dose proportionality. Peak/trough ratios were
approximately 1.9:1 for both doses. When concentrations
from each dose group were adjusted for dose, the normalized
values (ng/ml/mg) were similar, again indicating dose pro-
portionality. For all subsequent analyses, the data from both
doses were pooled (Table 1).
Demographics. Table 2 shows the impact of demographic
characteristics on dabigatran plasma concentrations. Only
trough concentrations are shown; unless otherwise speciﬁed,
similar relationships occurred for peak concentrations. Renal
function (CrCl) was a key determinant of plasma concen-
trations. The subjects with moderate renal impairment
(between 30 and 50 ml/min CrCl) showed a 2.29-fold
higher trough concentration than the subjects with renal
function undiminished by age (CrCl 80 ml/min). In the
subjects with mild renal impairment (between 50 and 80 ml/
min CrCl), the trough concentrations were 47% higher
compared with the subjects with CrCl 80 ml/min (0.828
ng/ml/mg vs. 0.564 ng/ml/mg).
Concentrations of dabigatran increased with age, with a
68% increase in trough concentrations in patients age 75
years compared with those <65 years. Renal function was
highly correlated with age. Concentrations in female subjects
were approximately 30% higher than those in male subjects.istration of Dabigatran 110 or DE 150, and
DE 150
(ng/ml)
DE 110 þ DE 150
(ng/ml/mg)
)
C2,ss
(n ¼ 4,600)
Cpre,ss
(n ¼ 8,449)
C2,ss
(n ¼ 9,183)
175 0.795 1.54
74.1 80.9 74.7
184 0.811 1.62
74.3 0.349 0.648
383 1.9 3.36
2.3 0.00923 0.0129
1,000 7.36 9.02
ncentration at steady state; DE ¼ dabigatran etexilate; DE 110 ¼ dabigatran etexilate 110 mg twice
an ¼ geometric mean; P10 ¼ 10th percentile; P90 ¼ 90th percentile.
Table 2
Dose-Normalized Plasma Concentrations (ng/ml/mg) of Dabigatran According to
Demographic Characteristics in the RE-LY Trial
Characteristic Measure Subgroup 1 Subgroup 2 Subgroup 3 Subgroup 4
Sex
Male
(n ¼ 5,524)
Female
(n ¼ 2,925)
gMean 0.727 0.942 d d
gCV, % 78.2 69.3 d d
Median 0.736 0.967 d d
P10 0.324 0.419 d d
P90 1.7 2.21 d d
Age, yrs
<65
(n ¼ 1,466)
65 to <75
(n ¼ 3,787)
75
(n ¼ 3,196)
gMean 0.586 0.749 0.982 d
gCV, % 86 75.2 76 d
Median 0.595 0.761 0.994 d
P10 0.241 0.341 0.45 d
P90 1.43 1.69 2.22 d
Weight, kg
<50
(n ¼ 163)
50 to <100
(n ¼ 6,852)
100
(n ¼ 1,433)
gMean 0.998 0.824 0.652 d
gCV, % 83.8 80.6 77.1 d
Median 1.01 0.84 0.66 d
P10 0.41 0.365 0.281 d
P90 2.63 1.94 1.56 d
CrCl, ml/min
<30
(n ¼ 18)
30 to <50
(n ¼ 1,512)
50 to <80
(n ¼ 3,937)
80
(n ¼ 2,690)
gMean 1.87 1.29 0.828 0.564
gCV, % 51.9 78 71.7 70.2
Median 2.11 1.33 0.857 0.582
P10 0.905 0.601 0.395 0.262
P90 3.16 2.83 1.77 1.2
CHADS2
0–1
(n ¼ 2,783)
2
(n ¼ 2,964)
3þ (>2)
(n ¼ 2,702)
gMean 0.688 0.808 0.908 d
gCV, % 76.4 79.2 83.5 d
Median 0.706 0.820 0.932 d
P10 0.318 0.355 0.390 d
P90 1.527 1.935 2.191 d
CHA2DS2-VASc
0–1
(n ¼ 282)
2
(n ¼ 1,663)
3þ (>2)
(n ¼ 6,504)
gMean 0.499 0.624 0.863 d
gCV, % 82.4 73.5 79.6 d
Median 0.513 0.636 0.887 d
P10 0.218 0.284 0.380 d
P90 1.115 1.376 2.10 d
HAS-BLED
0–1
(n ¼ 5,201)
2þ (>1)
(n ¼ 3,248)
gMean 0.701 0.972
gCV, % 76.5 81.3
Median 0.715 0.989
P10 0.316 0.415
P90 1.571 2.290
Abbreviations as in Table 1.
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324Weight under 50 kg was associated with a geometric mean
concentration of DE 21% higher than for subjects weighing
50 to 100 kg, and 53% higher than patients weighing
100 kg. Risk scores for stroke and bleeding were positively
correlated with plasma concentrations. For ethnicity andgeographic regional variation, there were no relevant differ-
ences in plasma concentrations (Online Tables 2 and 3).
Plasma concentrations and outcome events. On average,
subjects who had a major bleeding event during the trial had
higher trough and post-dose concentrations than subjects
Table 3 Trough Concentrations of Dabigatran (ng/ml/mg) Grouped by Outcome Event Occurrence
Major
Bleed
(n ¼ 323)
Any
Bleed
(n ¼ 2,319)
No
Bleed
(n ¼ 5,899)
Stroke/SEE
(þ)
(n ¼ 129)
No Stroke/SEE
()
(n ¼ 8,250)
Stroke/SEE/Death
(þ)
(n ¼ 387)
No Stroke/SEE/Death
()
(n ¼ 7,789)
CV Events*
(þ)
(n ¼ 391)
No CV Events
()
(n ¼ 7,865)
gMean 113 86.9 72.8 76.6 76.5 88.5 75.4 87.8 75.6
gCV, % 79.8 81.4 84 84.1 83.9 84.7 83.3 89.5 83.1
Median 116 88.2 75.3 80.6 78.3 91.4 77.6 90.7 77.6
P10 46.7 35.7 30.7 26.4 32.1 33.1 31.8 31.2 32
P90 269 211 175 185 186 226 181 229 182
*Cardiovascular (CV) events include stroke, systemic embolism, pulmonary embolism, myocardial infarction, and vascular deaths.
(þ) ¼ with event on-treatment; () ¼ without event; other abbreviations as in Table 1.
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325without bleeding events. The median trough and post-dose
concentrations were 55% and 36% higher, respectively, in
the subjects with a major bleeding event than those in the
subjects without bleeding events. Median (10th to 90th
percentiles) trough concentrations in 323 patients with
major bleeds were 116 (46.7 to 269) ng/ml compared with
75.3 (30.7 to 175) ng/ml in 5,899 patients with no major
bleed (Table 3). Plasma concentrations of dabigatran were
higher in subjects with hemorrhagic stroke (n ¼ 11 with
trough and 13 with peak measurements) than in the subjects
(n ¼ 8,269 with trough and 8,971 with peak measurements)
without hemorrhagic stroke (144 ng/ml vs. 78.4 ng/ml for
trough and 241 ng/ml vs. 155 ng/ml for post-dose
concentrations, respectively; p > 0.05). Median plasma
concentrations in subjects with an ischemic stroke or SEE
were not different from those without these events.
In multivariate analyses of dabigatran concentrations
versus both ischemic and bleeding outcomes, CrCl and age
had similar predictive values as covariates, but they were
highly correlated. In logistic regression analyses with trough
concentration and age in the model, CrCl was not
signiﬁcant.
The relationship between major bleeding and trough
plasma concentrations was analyzed by logistic regressionFigure 1 Probability of Clinical Outcomes Versus Dabigatran Plasma
Major bleeding event (left) and ischemic stroke/systemic embolic event (right) versus tro
85 years). Covariates include sex, prior stroke, and diabetes. Conc. ¼ concentration.analyses with and without covariates. The best-ﬁt model
(c-statistic 0.715, 95% conﬁdence interval [CI]: 0.69
to 0.74) included trough concentration (p < 0.0001), age
(p < 0.0001), ASA use (p ¼ 0.0003), diabetes (p ¼ 0.018),
clopidogrel use (p ¼ 0.076), sex (p ¼ 0.078), and CAD
(p ¼ 0.107). Without plasma concentrations in the model,
the c-statistic was 0.68. Figure 1 shows the risk of major
bleeding and ischemic stroke/SEE versus trough concen-
tration at different ages. The model showed an acceptable
predictive performance of the bleeding events using the
validation dataset (55 patients with major bleed events on-
treatment, 3,464 patients without an event). The Hosmer-
Lemeshow goodness-of-ﬁt test was p ¼ 0.082, indicating
no signiﬁcant difference between observed and predicted
events (Online Fig. 1).
In the multivariate analysis of ischemic stroke/SEE,
there was an inverse relation between dabigatran trough
concentrations and the probability of an event. The best-
ﬁt logistic regression model (c-statistic 0.657, 95% CI:
0.61 to 0.71) included age (p < 0.0001), previous stroke/
transient ischemic attack (p < 0.0001), trough concentration
(p < 0.045), and diabetes at baseline (p ¼ 0.167). Without
plasma concentrations in the model, the c-statistic was 0.64.
ASA use was not a signiﬁcant covariate. For the validationConcentrations
ugh dabigatran plasma concentration in atrial ﬁbrillation patients by age (65, 75, and
Figure 2
Probability of Major Bleeding Event and Ischemic
Stroke/SEE Versus Trough Plasma Concentration of
Dabigatran
Calculated for 72-year-old male atrial ﬁbrillation patient with prior stroke and
diabetes. Lines and boxes at the top of the panel indicate median dabigatran
concentrations in the RE-LY trial with 10th and 90th percentiles.
Conc.¼ concentration;DE¼ dabigatranetexilate; SEE¼ systemic embolic event(s).
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326dataset (183 patients with ischemic stroke/SEE events
on-treatment, 3,304 patients without event), the Hosmer-
Lemeshow goodness-of-ﬁt test was p ¼ 0.217, indicating
a good ﬁt. The slope of the concentration response curve for
ischemic stroke/SEE was steepest at low concentrations
(Figs. 1 and 2). A comparison of beneﬁt and risk based on
the logistic regression curves for major bleeding and
ischemic stroke/SEE is shown in Figure 2 for a 72-year-old
male patient with prior stroke and diabetes, together with
the predicted median concentrations and 10th and 90th
percentiles, for DE 110 and DE 150.
A Cox regression splines analysis of time to ﬁrst major
bleed with trough concentration, age, and CHADS2 score asFigure 3 Cox Regression Analyses of Ischemic Stroke/SEE and Maj
The graphs show the hazard ratio (HR) of risk of event versus median trough dabigatran con
(71 years). Note log2 scale for concentrations. CI ¼ conﬁdence interval; other abbreviaticovariates showed that, compared with the median trough
concentration of 88 ng/ml, adjusted for age and CHADS2
score, the rate of major bleeding doubled at a concentration
of 210 ng/ml (Fig. 3). Similarly, a Cox regression analysis
of time to ﬁrst ischemic stroke/SEE, with trough concen-
tration, age, and CHADS2 score as independent covariates,
showed that the relative risk of ischemic stroke/SEE was
increased by 50% at a concentration of 28 ng/ml compared
with the risk at median trough concentrations (59 ng/ml)
(Fig. 3).Discussion
In this exposure response analysis from the RE-LY trial, the
risks of major bleeding and ischemic stroke/SEE after
dosing with DE 110 or DE 150 in patients with AF were
related to trough concentrations of dabigatran. Signiﬁcant
factors affecting dabigatran plasma concentrations were age,
CrCl, weight, and sex. Of these, all but weight are inde-
pendent risk factors for stroke and bleeding risk in patients
with AF.
The magnitude of the effect of dabigatran plasma
concentrations on outcomes in AF patients in RE-LY
depends strongly on demographic factors, most impor-
tantly increasing age. In multivariate analyses, age was the
strongest independent covariate for prediction of a relation-
ship between plasma concentration and outcome events, but
age >75 years is also directly related to the risk of strokes
and bleeds in AF patients. As can be seen from Figure 1 and
Table 1, plasma concentrations increase approximately 67%
in patients age >75 years compared with those <65 years,
but major bleed risk and stroke risk increase 2- to 3-fold.
The effect of age on dabigatran exposure is likely due to the
decreasing renal function in the elderly. Concentrations are
increased 1.8-fold and 1.2-fold for patients with CrCl of 30
or 50 ml/min, respectively, compared with the median CrCl
of 69 ml/min in RE-LY patients. In RE-LY, approximatelyor Bleeding Versus Trough Plasma Concentration of Dabigatran
centration (vertical line) in patients with median CHADS2 score (2.0) and median age
ons as in Figure 2.
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32735% of patients 75 years had moderate renal dysfunction
(CrCl 30 to 50 ml/min), and the median dabigatran
concentration in patients 75 years was 39% higher than in
patients <75 years (Table 2). Renal function, as measured
by calculated CrCl, is no longer signiﬁcant with age in
the equation, although approximately 80% to 85% of dabi-
gatran is excreted renally (6). Despite increased rates of
major bleeding with decreasing renal function in DE pati-
ents, the relative risk of bleeding compared with warfarin
did not change (7), suggesting that age and other factors in
addition to anticoagulant effect or exposure play a role in the
increased risk of stroke and bleeding seen in patients with
renal dysfunction. Plasma concentrations also rose with
increases in standard risk scores (Table 2). This likely reﬂects
the negative impact of comorbidities and increasing age on
renal clearance of dabigatran and further emphasizes the
strong interaction between risk factors, plasma concentra-
tions, and outcomes.
The concentration range achieved for either dose in
RE-LY ranged over 5-fold for the 10th to 90th percentiles,
with a large overlap of concentrations, approximately 70%,
between the 2 doses. Given that the primary analyses of the
whole population, without consideration of plasma levels,
showed that the 2 doses of DE in RE-LY were effective and
safe, this suggests that there is a wide therapeutic range.
Nevertheless, there is a relevant effect of plasma concen-
trations on outcomes, with the c-statistic increasing from
0.64 to 0.66 for ischemic stroke/SEE and 0.68 to 0.72 for
major bleeding. In some patients who are at the extremes of
the concentration range and have 1 or more risk factors
such as old age, reduced CrCl, or low body weight, better
outcomes might be achieved by adjusting the dose.
Across the 10th to 90th percentile range of steady-state
trough plasma concentrations achieved for the 150-mg bid
dose, the overall risk of major bleeding during the trial ranges
from approximately 2% to 7% (approximately 1.0% to 3.5%
per year), with substantial impact of age and concomitant
antiplatelet use, with sex, history of diabetes, and CAD also
signiﬁcant covariates in the model. Case reports of bleeding
associated with extremely high DE plasma concentrations,
over 2,000 ng/ml, have been reported (11). However, a lower
dose to reduce bleeding must be weighed against the accom-
panying stroke risk, which increases with decreasing plasma
concentrations. The risk of ischemic stroke over the same
concentration range shows only a limited variation, for
example, from 1.1% to 1.5% for a 72-year-old AF patient and
1.5% to 2.1% for an 80-year-old patient.
Because the risk of ischemic events is relatively constant
for patients with higher plasma concentrations, reducing the
daily dose in such patients may reduce the risk of bleeding
without an appreciable loss of efﬁcacy (Fig. 2). Older
patients, those with multiple comorbidities, or those with
reduced renal function may be appropriate candidates for
a lower dose. Similarly, at concentrations below 28 ng/ml,
for example, the 10th percentile for the 110-mg bid dose,
the risk of ischemic events is high, but bleed risk is low. Anupward adjustment of dose in patients with very low plasma
concentrations should improve their risk–beneﬁt ratio.
However, this hypothesis should be tested in a controlled
trial. The large majority of patients achieve a favorable
balance of beneﬁt and risk with a ﬁxed dose of DE 110 or
DE 150, guided by a consideration of patient characteristics.
Correlations of dabigatran plasma concentrations with
bleeding and venous thromboembolism were previously used
to support dose selection in an orthopedic surgery pop-
ulation (12). A dose response in AF patients has been
previously demonstrated for DE for minor bleeding at doses
from 100 to 600 mg/day (13). Long-term follow-up of these
patients over 4 years has also demonstrated a dose response
for major bleeding and for ischemic stroke and systemic
embolism (14). Doses of 150 mg/day or less were inadequate
for stroke prevention, and 600 mg/day led to high rates of
major bleeding. However, none of these studies adjusted the
dose based on plasma concentrations of dabigatran.
Attempts to identify an optimal beneﬁt–risk range for other
antithrombotic medications based on clinical outcome
events have met with mixed success for warfarin (15),
ximelagatran (16), fondaparinux (17), and rivaroxaban (18).
Application of ﬁndings to clinical practice. In this RE-LY
substudy, demographic characteristics played the strongest
role in determining risk of clinical events. In patients at
highest risk for events, such as the very elderly and/or those
with poor renal function, an adjustment of DE dose to
optimize exposure might improve the beneﬁt–risk if they
are at either extreme of the concentration range. However, an
assay of dabigatran concentrations is not yet widely available,
and at least in the United States, only the 150-mg bid dose is
available except for a 75-mg bid dose in patients with severe
renal failure. This substudy, therefore, can only serve as
a basis for future endeavors in this area.
Study strengths and limitations. The size and scope of the
plasma sampling of dabigatran in the RE-LY trial have
permitted an analysis of the relationship between clinical
outcomes and plasma concentrations of dabigatran, as well
as the impact of demographic characteristics in patients with
AF. Over 70% of the 12,091 patients randomized to DE
had at least 1 plasma sample on-treatment. An assessment of
beneﬁt–risk is based on the primary safety and efﬁcacy
outcomes rather than laboratory measurement of anticoag-
ulant activity.
This study has several limitations. Although the association
of clinical outcomes with dabigatran concentrations was pre-
speciﬁed in the main study protocol, not all patients
randomized to DE contributed a blood sample. This may
have introduced some bias. Nevertheless, as demonstrated
by goodness-of-ﬁt estimates, predicted event rates in the
patients who were not sampled agreed with the observed
rates. Most of the blood sampling was carried out after
1 month on-treatment, at steady state, so early discontinua-
tion of treatment for stroke or bleeding is not accounted for.
Only patients who were on-treatment at the time of sampling
and the time of the clinical event are included. There was no
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Medication compliance was not assessed in this analysis,
which may introduce additional variability. Thus, intra-
individual variability in plasma concentrations over time may
blur the associations between dabigatran concentration and
outcomes.
Conclusions
Both doses of DE in RE-LY were associated with a more
than 5-fold variation in plasma concentrations, indicating
a wide therapeutic range. Renal function was the predomi-
nant patient characteristic that determined plasma concen-
trations. Safety and efﬁcacy outcomes were correlated with
plasma concentrations of dabigatran, with age as the most
important covariate. There is no single plasma concentration
range that provides optimal beneﬁt–risk for all patients. The
balance between stroke risk and bleed risk varied with
concentration, suggesting that there is a subset of AF
patients who may improve their beneﬁt–risk balance with
DE by a tailoring of the dose in relation to patient
characteristics.
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